• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综述:鼻腔作为治疗途径。第二部分 免疫疗法。

Review: The Nose as a Route for Therapy. Part 2 Immunotherapy.

作者信息

Padayachee Yorissa, Flicker Sabine, Linton Sophia, Cafferkey John, Kon Onn Min, Johnston Sebastian L, Ellis Anne K, Desrosiers Martin, Turner Paul, Valenta Rudolf, Scadding Glenis Kathleen

机构信息

Department of Respiratory Medicine, Faculty of Medicine, Imperial College Healthcare NHS Trust, Imperial College London, London, United Kingdom.

Center for Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.

出版信息

Front Allergy. 2021 Jul 1;2:668781. doi: 10.3389/falgy.2021.668781. eCollection 2021.

DOI:10.3389/falgy.2021.668781
PMID:35387044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8974912/
Abstract

The nose provides a route of access to the body for inhalants and fluids. Unsurprisingly it has a strong immune defense system, with involvement of innate (e.g., epithelial barrier, muco- ciliary clearance, nasal secretions with interferons, lysozyme, nitric oxide) and acquired (e.g., secreted immunoglobulins, lymphocytes) arms. The lattice network of dendritic cells surrounding the nostrils allows rapid uptake and sampling of molecules able to negotiate the epithelial barrier. Despite this many respiratory infections, including SARS-CoV2, are initiated through nasal mucosal contact, and the nasal mucosa is a significant "reservoir" for microbes including . This review includes consideration of the augmentation of immune defense by the nasal application of interferons, then the reduction of unnecessary inflammation and infection by alteration of the nasal microbiome. The nasal mucosa and associated lymphoid tissue (nasopharynx-associated lymphoid tissue, NALT) provides an important site for vaccine delivery, with cold-adapted live influenza strains (LAIV), which replicate intranasally, resulting in an immune response without significant clinical symptoms, being the most successful thus far. Finally, the clever intranasal application of antibodies bispecific for allergens and Intercellular Adhesion Molecule 1 (ICAM-1) as a topical treatment for allergic and RV-induced rhinitis is explained.

摘要

鼻子为吸入剂和液体进入人体提供了一条途径。不出所料,它拥有强大的免疫防御系统,涉及先天性(如上皮屏障、黏液纤毛清除、含有干扰素、溶菌酶、一氧化氮的鼻分泌物)和后天性(如分泌型免疫球蛋白、淋巴细胞)分支。鼻孔周围的树突状细胞晶格网络能够快速摄取和采样能够穿透上皮屏障的分子。尽管如此,包括SARS-CoV2在内的许多呼吸道感染都是通过鼻黏膜接触引发的,鼻黏膜是包括……在内的微生物的重要“储存库”。本综述包括考虑通过鼻腔应用干扰素增强免疫防御,然后通过改变鼻腔微生物群减少不必要的炎症和感染。鼻黏膜和相关淋巴组织(鼻咽炎相关淋巴组织,NALT)为疫苗接种提供了一个重要部位,冷适应活流感病毒株(LAIV)在鼻内复制,可引发免疫反应且无明显临床症状,是迄今为止最成功的。最后,解释了将对过敏原和细胞间黏附分子1(ICAM-1)具有双特异性的抗体巧妙地经鼻应用作为过敏性和RV诱导性鼻炎的局部治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdc2/8974912/cd21c283c184/falgy-02-668781-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdc2/8974912/061d4c9413fd/falgy-02-668781-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdc2/8974912/cd21c283c184/falgy-02-668781-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdc2/8974912/061d4c9413fd/falgy-02-668781-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdc2/8974912/cd21c283c184/falgy-02-668781-g0002.jpg

相似文献

1
Review: The Nose as a Route for Therapy. Part 2 Immunotherapy.综述:鼻腔作为治疗途径。第二部分 免疫疗法。
Front Allergy. 2021 Jul 1;2:668781. doi: 10.3389/falgy.2021.668781. eCollection 2021.
2
Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences.经鼻内途径进行黏膜疫苗接种。鼻相关淋巴组织(NALT)——结构、功能及种属差异。
Vaccine. 2015 Aug 26;33(36):4406-13. doi: 10.1016/j.vaccine.2015.07.022. Epub 2015 Jul 18.
3
Antibody Conjugates Bispecific for Pollen Allergens and ICAM-1 with Potential to Prevent Epithelial Allergen Transmigration and Rhinovirus Infection.针对花粉过敏原和 ICAM-1 的双特异性抗体缀合物,具有预防上皮过敏原迁移和鼻病毒感染的潜力。
Int J Mol Sci. 2023 Feb 1;24(3):2725. doi: 10.3390/ijms24032725.
4
Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.口腔细菌与鼻腔疫苗联合使用可预防甲型流感病毒和 SARS-CoV-2 感染。
mBio. 2021 Aug 31;12(4):e0159821. doi: 10.1128/mBio.01598-21. Epub 2021 Aug 17.
5
Activation and Induction of Antigen-Specific T Follicular Helper Cells Play a Critical Role in Live-Attenuated Influenza Vaccine-Induced Human Mucosal Anti-influenza Antibody Response.抗原特异性滤泡辅助 T 细胞的激活和诱导在活流感减毒疫苗诱导的人体黏膜抗流感抗体反应中发挥关键作用。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00114-18. Print 2018 Jun 1.
6
Live attenuated influenza vaccine strains elicit a greater innate immune response than antigenically-matched seasonal influenza viruses during infection of human nasal epithelial cell cultures.减毒流感疫苗株在感染人鼻腔上皮细胞培养物时,比抗原匹配的季节性流感病毒引起更大的先天免疫反应。
Vaccine. 2014 Mar 26;32(15):1761-7. doi: 10.1016/j.vaccine.2013.12.069. Epub 2014 Jan 30.
7
[Rhinitis in adults].[成人鼻炎]
Acta Med Croatica. 2011;65(2):181-7.
8
Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.对葡萄球菌中毒性休克的鼻腔免疫由鼻咽相关淋巴组织控制。
Clin Vaccine Immunol. 2011 Apr;18(4):667-75. doi: 10.1128/CVI.00477-10. Epub 2011 Feb 16.
9
Euphorbium compositum SN improves the innate defenses of the airway mucosal barrier network during rhinovirus infection.复方莪术油 SN 可改善鼻病毒感染期间气道黏膜屏障网络的固有防御功能。
Respir Res. 2024 Nov 13;25(1):407. doi: 10.1186/s12931-024-03030-7.
10
Expression of intercellular adhesion molecule-1 (ICAM-1) in nasal epithelial cells of atopic subjects: a mechanism for increased rhinovirus infection?特应性个体鼻上皮细胞中细胞间黏附分子-1(ICAM-1)的表达:鼻病毒感染增加的一种机制?
Clin Exp Immunol. 2000 Aug;121(2):339-45. doi: 10.1046/j.1365-2249.2000.01301.x.

引用本文的文献

1
Single-Domain Antibodies-Novel Tools to Study and Treat Allergies.单域抗体——研究和治疗过敏的新工具。
Int J Mol Sci. 2024 Jul 11;25(14):7602. doi: 10.3390/ijms25147602.
2
Post-exposure intranasal IFNα suppresses replication and neuroinvasion of Venezuelan Equine Encephalitis virus within olfactory sensory neurons.暴露后鼻腔内给予 IFNα 可抑制嗅觉感觉神经元内委内瑞拉马脑炎病毒的复制和神经侵袭。
J Neuroinflammation. 2024 Jan 17;21(1):24. doi: 10.1186/s12974-023-02960-1.
3
Antibody Conjugates Bispecific for Pollen Allergens and ICAM-1 with Potential to Prevent Epithelial Allergen Transmigration and Rhinovirus Infection.

本文引用的文献

1
An Experience with Cuban Biotech's Nasalferon to Prevent SARS-COV-2 Infections in International Travelers and their Contacts.古巴生物技术公司的鼻用干扰素预防国际旅行者及其接触者感染新冠病毒的经验。
MEDICC Rev. 2021 Apr;23(2):10. doi: 10.37757/MR2021.V23.N2.1. Epub 2021 Apr 2.
2
The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area.重组人干扰素 α 鼻用喷雾剂对疫区医务人员预防 COVID-19 肺炎的效果。
Curr Top Med Chem. 2021;21(10):920-927. doi: 10.2174/1568026621666210429083050.
3
COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters.
针对花粉过敏原和 ICAM-1 的双特异性抗体缀合物,具有预防上皮过敏原迁移和鼻病毒感染的潜力。
Int J Mol Sci. 2023 Feb 1;24(3):2725. doi: 10.3390/ijms24032725.
4
Generation of high affinity ICAM-1-specific nanobodies and evaluation of their suitability for allergy treatment.生成高亲和力 ICAM-1 特异性纳米抗体及其用于过敏治疗的适用性评估。
Front Immunol. 2022 Nov 9;13:1022418. doi: 10.3389/fimmu.2022.1022418. eCollection 2022.
5
A New Grand Challenge in Rhinology: An Intranasal COVID Vaccine.鼻科学的一项新重大挑战:鼻内新冠疫苗
Front Allergy. 2022 May 20;3:881118. doi: 10.3389/falgy.2022.881118. eCollection 2022.
与COVID-19相关的嗅觉丧失与人类嗅觉上皮中的病毒持续存在和炎症以及仓鼠的脑部感染有关。
Sci Transl Med. 2021 Jun 2;13(596). doi: 10.1126/scitranslmed.abf8396. Epub 2021 May 3.
4
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.干扰素治疗在重症 COVID-19 中的作用:COVIFERON 随机对照试验。
Sci Rep. 2021 Apr 13;11(1):8059. doi: 10.1038/s41598-021-86859-y.
5
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.佩格干扰素 lambda-1a 治疗门诊轻至中度 COVID-19 患者的随机安慰剂对照试验。
Nat Commun. 2021 Mar 30;12(1):1967. doi: 10.1038/s41467-021-22177-1.
6
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.聚乙二醇干扰素 alfa-2b 在中度 COVID-19 中的疗效和安全性:一项 II 期、随机、对照、开放标签研究。
Int J Infect Dis. 2021 Apr;105:516-521. doi: 10.1016/j.ijid.2021.03.015. Epub 2021 Mar 10.
7
Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.基因工程干扰素-α与传统干扰素-α治疗中重度 COVID-19 的效果:一项随机临床试验。
Ann Med. 2021 Dec;53(1):391-401. doi: 10.1080/07853890.2021.1890329.
8
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.佩格干扰素 lambda 治疗 COVID-19 门诊患者:一项 2 期、安慰剂对照随机试验。
Lancet Respir Med. 2021 May;9(5):498-510. doi: 10.1016/S2213-2600(20)30566-X. Epub 2021 Feb 5.
9
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
10
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.吸入用干扰素 β-1a(SNG001)治疗 SARS-CoV-2 感染的安全性和有效性:一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12.